Skip to main content
. 2001 May;75(10):4604–4613. doi: 10.1128/JVI.75.10.4604-4613.2001

FIG. 7.

FIG. 7

Binding of hPIV-1 clinical isolates to gangliosides in solid-phase binding assays. The binding activities of hPIV-1 clinical isolates Cl-5, Cl-11, and Cl-14 were calculated as described in the legend to Fig. 2. Symbols: ●, NeuAcα2–3I; ○, NeuAcα2–6I; ▴, NeuAcα2–6SPG; ▵, GD1a; ▪, GM1a; □, GM3.

HHS Vulnerability Disclosure